FDA approves Lilly's EBGLYSS for eight-week dosing in atopic dermatitis
Tweet Send to a Friend
The U.S. Food and Drug Administration approved a new dosing regimen for Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
